8-K: TuHURA Biosciences Announces Phase 3 Trial for IFx-2.0 and Potential Merger with Kineta

TuHURA Biosciences is advancing its lead candidate, IFx-2.0, into a Phase 3 trial and has entered a non-binding letter of intent for a potential merger with Kineta, Inc.

Summary

• TuHURA Biosciences has announced a single Phase 3 accelerated approval registration trial for its IFx-2.0 therapy in the first half of 2025 for Merkel Cell Carcinoma.
• The trial is under a Special Protocol Assessment (SPA) agreement with the FDA and will include Overall Response Rate (ORR) as the primary endpoint and Progression-Free Survival (PFS) as a key secondary endpoint.
• The company has entered a non-binding letter of intent to acquire Kineta's KVA12123 VISTA inhibiting antibody through a merger, which would add a Phase 2 ready asset to their pipeline.
• TuHURA is also advancing its IFx-3.0 program, a systemically administered tumor-targeted mRNA innate immune response agonist for aggressive B Cell Lymphoma.
• The company is developing bi-specific antibody drug conjugates (ADCs) or peptide drug conjugates (PDCs) targeting Myeloid Derived Suppressor Cells (MDSCs).
• TuHURA has expanded its leadership team with the appointments of Peter O'Neill as Vice President, Clinical Operations and Michael Krsulich as Head of Quality Assurance.
• A $31 million financing was completed in connection with the merger with Kintara, expected to fund operations into the second half of 2025.
• An additional $5 million was raised to fund the Exclusivity and Right of First Offer Agreement with Kineta.

Sentiment

Score: 8

Explanation: The document is positive due to the advancement of the lead program to Phase 3, the potential acquisition of a new asset, and the secured funding. The addition of experienced management also contributes to the positive sentiment. However, the potential risks associated with the merger and clinical trials temper the overall optimism.

Positives

• The IFx-2.0 program is progressing to a Phase 3 trial with a clear regulatory pathway via the SPA agreement with the FDA.
• The potential acquisition of KVA12123 would add a promising Phase 2 ready asset to TuHURA's pipeline.
• The company has secured $31 million in funding, which is expected to support operations into the second half of 2025.
• The company is expanding its leadership team with experienced professionals.
• The FDA's Project Front Runner initiative supports the development of IFx-2.0 in the first-line setting.
• The trial design includes a key secondary endpoint of PFS, which could lead to full approval.

Negatives

• The merger with Kineta is still subject to a definitive agreement and may not be completed.
• The REM-001 program is being considered for licensing, indicating a shift in focus away from this asset.
• The company is relying on forward-looking statements, which are not guarantees of future performance.

Risks

• The potential merger with Kineta is subject to negotiation and may not be finalized.
• Clinical trial results may not be positive, and the IFx-2.0 program may not achieve its endpoints.
• The company's financial resources may not be sufficient to fund all planned operations.
• The development of new technologies is subject to inherent risks and uncertainties.
• The company is subject to regulatory risks and may not receive necessary approvals.

Future Outlook

TuHURA anticipates initiating a Phase 3 trial for IFx-2.0 in the first half of 2025 and aims to complete the acquisition of Kineta's KVA12123, subject to a definitive agreement. The company also plans to advance its other pipeline programs and seek licensing opportunities for REM-001.

Management Comments

• James Bianco, M.D., President and Chief Executive Officer of TuHURA, stated that the single registration directed trial for IFx-2.0, with its primary endpoint of Overall Response Rate (ORR) and key secondary endpoint of Progression-Free Survival (PFS), could potentially convert accelerated approval to full approval.
• Dr. Bianco also commented that the potential acquisition of KVA12123 would bring a Phase 2 ready candidate with therapeutic synergies across their pipeline and technologies.
• Dr. Bianco expressed excitement about strengthening the leadership team with the appointments of Peter O'Neill and Michael Krsulich.

Industry Context

This announcement reflects the ongoing trend in the immuno-oncology space towards developing novel therapies that overcome resistance to existing treatments. The focus on innate immune response agonists and tumor microenvironment modulators aligns with current research and development efforts in the field. The potential acquisition of a VISTA inhibitor also highlights the interest in targeting new immune checkpoints.

Comparison to Industry Standards

• The development of IFx-2.0 as an adjunctive therapy to Keytruda (pembrolizumab) is consistent with the industry trend of combining immunotherapies to improve efficacy, similar to trials being conducted by companies like Bristol Myers Squibb and Merck.
• The focus on overcoming resistance to checkpoint inhibitors is a common goal in the immuno-oncology field, with companies like Adaptimmune and Iovance Biotherapeutics also working on similar approaches.
• The development of bi-specific ADCs and PDCs targeting MDSCs is a novel approach, but other companies like Amgen and Regeneron are also exploring bi-specific antibodies for cancer treatment.
• The potential acquisition of KVA12123 is similar to other companies acquiring assets to expand their pipelines, such as Gilead's acquisition of Immunomedics.

Management Changes

Stakeholder Impact

• Shareholders may benefit from the potential acquisition and advancement of the pipeline.
• Employees may experience changes due to the merger and new management appointments.
• Patients may benefit from the development of new cancer therapies.
• Creditors may be impacted by the company's financial performance and potential merger.

Next Steps

• Reach a potential definitive agreement for the acquisition of KVA12123 in Q4 2024.
• Initiate the IFx-2.0 Phase 3 trial in H1 2025.
• Complete the potential acquisition of Kinetas KVA12123 in H1 2025.
• Commence VISTA inhibiting Mab Phase 2 trials in H2 2025 (if the Kineta merger is completed).
• Advance Bi-specific MDSC targeted ADC in vivo POC in H2 2025.
• Advance IFx-3.0: CD22+ tumor targeted mRNA in vivo POC studies in H2 2025.
• Seek licensing opportunities for REM-001.

Key Dates

Keywords

IFx-2.0, Merkel Cell Carcinoma, KVA12123, VISTA Inhibitor, Phase 3 Trial, Merger, Kineta, Immunotherapy, FDA, Clinical Trial, Oncology, ADC, PDC, MDSC